Please login to the form below

Not currently logged in
Email:
Password:

MHRA chair Breckenridge to advise UK on healthcare ethics

Sir Alasdair Breckenridge appointed first chair of the Emerging Science and Bioethics Advisory Committee

Professor Sir Alasdair Breckenridge - MHRA chairChair of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Sir Alasdair Breckenridge, has been appointed the first chair of the Emerging Science and Bioethics Advisory Committee at the country's Department of Health (DH).

The new committee has been formed to advise UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications.

"I am delighted that Sir Alasdair has agreed to chair this important new committee,” said the DH's chief medical officer, Dame Sally Davies.

“He brings with him a level of experience that is difficult to match, plus a reputation for delivering high calibre debate and advice on serious scientific issues.”

In addition to his MHRA experience, Sir Alasdair's previous roles include serving as a member of the Adverse Reactions Group, and the Subcommittee on Adverse Reactions to Vaccines and Immunisation of the MHRA precursor, the Committee on Safety of Medicines (CSM).

Between 1992 and 1996 he was a member of the Medical Research Council, and he has worked closely on several programmes of the European Union, the World Health Organization and the International Union of Pharmacology.

Sir Alasdair takes up the position immediately, and will remain in the role for two years while also serving for the MHRA.

23rd May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics